Faruqi & Faruqi, LLP Announces Investigation of Dendreon Corporation

Faruqi & Faruqi, LLP announced that it is investigating potential wrongdoing at Dendreon Corp. Faruqi & Faruqi, LLP seeks to determine whether Dendreon violated federal securities laws in connection with statements made to the Company’s shareholders. Specifically, the investigation focuses on whether certain individuals violated federal securities laws by, among other things, failing to disclose that: physicians were not adopting the Company’s new PROVENGE cancer drug as expected due to concerns of insurance reimbursement and over concerns that the drug was extremely expensive, relative to its results; sales forecasts based on physicians’ immediate adoption of PROVENGE were dramatically inflated because of a lack of options to finance these expensive treatments; and the Company did not have adequate systems of internal operational or financial controls.